Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein

(2018) Michael D. Oberst et al.   MOLECULAR CANCER THERAPEUTICS

Structural principles of tumor necrosis factor superfamily signaling

(2018) Éva S. Vanamee et al.   Science Signaling

Structural principles of tumor necrosis factor superfamily signaling

(2018) Éva S. Vanamee et al.   Science Signaling

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

(2017) Rajeev K. Shrimali et al.   Cancer Immunology Research

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

(2017) Natalie J. Tigue et al.   OncoImmunology

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody

(2016) Di Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination

(2016) G. Fromm et al.   Cancer Immunology Research

Principles of antibody-mediated TNF receptor activation

(2015) H Wajant   CELL DEATH AND DIFFERENTIATION

The multiple facets of FcRn in immunity

(2015) Nigel M. Stapleton et al.   IMMUNOLOGICAL REVIEWS

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy

(2012) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

OX40 Complexes with Phosphoinositide 3-Kinase and Protein Kinase B (PKB) To Augment TCR-Dependent PKB Signaling

(2011) T. So et al.   JOURNAL OF IMMUNOLOGY

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

New flow cytometric assays for monitoring cell-mediated cytotoxicity

(2010) Liubov Zaritskaya et al.   Expert Review of Vaccines

Construction and Preclinical Characterization of Fc-mGITRL for the Immunotherapy of Cancer

(2008) P. Hu et al.   CLINICAL CANCER RESEARCH

Targeting Cell Death in Tumors by Activating Caspases

(2008) A. Clark et al.   CURRENT CANCER DRUG TARGETS

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

(2008) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA